[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bayer A G Ord (BAYZF)

Bayer A G Ord (BAYZF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow 20.57
  • Price/Book 5.23
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield (Fwd) N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector N/A
  • INDUSTRY GROUPING N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
41.7300 +7.85%
on 04/29/26
47.6200 -5.49%
on 04/22/26
-2.0093 (-4.27%)
since 04/21/26
3-Month
41.3100 +8.94%
on 03/04/26
51.0000 -11.75%
on 02/23/26
-6.0550 (-11.86%)
since 02/20/26
52-Week
27.1380 +65.84%
on 05/22/25
58.3276 -22.84%
on 02/17/26
+18.3250 (+68.68%)
since 05/21/25

Most Recent Stories

More News
ASCO 2026: Bayer to Present New Data Across Oncology Portfolio

Primary results from the Phase II ARACOG (AFT-47) head-to-head trial evaluating NUBEQA ® (darolutamide) versus enzalutamide in men with metastatic and non-metastatic castration-resistant...

BAYRY : 11.1100 (-1.51%)
BAYZF : 45.0050 (-0.89%)
BAYN : 0.0100 (unch)
Bayer’s KERENDIA® (finerenone) Granted Priority Review of Supplemental New Drug Application by U.S. FDA for Treatment of Adults with Type 1 Diabetes and Chronic Kidney Disease

If approved for this investigational new use, KERENDIA ® (finerenone), a non-steroidal mineralocorticoid antagonist (MRA), would be the first MRA indicated for adults with type 1 diabetes...

BAYRY : 11.1100 (-1.51%)
BAYZF : 45.0050 (-0.89%)
BAYN : 0.0100 (unch)
Bayer Granted Priority Review by U.S. FDA for Asundexian in Patients After a Non-Cardioembolic Ischemic Stroke or Transient Ischemic Attack

KEY FACTS: Regulatory submission is based on positive results from the Phase III OCEANIC-STROKE study OCEANIC-STROKE met the primary efficacy outcome...

BAYRY : 11.1100 (-1.51%)
BAYZF : 45.0050 (-0.89%)
BAYN : 0.0100 (unch)
U.S. FDA Grants Priority Review to Supplemental New Drug Application for HYRNUO® (sevabertinib) Under Investigation as a First-Line Treatment of HER2-Mutated Non-Small Cell Lung Cancer

Regulatory submission for first-line use of HYRNUO is based on results from the ongoing Phase I/II SOHO-01 trial evaluating the efficacy and safety in patients with advanced HER2 -mutated...

BAYRY : 11.1100 (-1.51%)
BAYZF : 45.0050 (-0.89%)
BAYN : 0.0100 (unch)
AUA 2026: Phase II ARASEC Data Further Supports the Efficacy and Safety of NUBEQA® (darolutamide) Plus ADT in Patients with Metastatic Castration-Sensitive Prostate Cancer

Primary results from the Phase II ARASEC trial show that NUBEQA ® (darolutamide) plus androgen deprivation therapy (ADT) showed a statistically significant improvement in progression-free...

BAYRY : 11.1100 (-1.51%)
BAYZF : 45.0050 (-0.89%)
BAYN : 0.0100 (unch)
Bayer Introduces Midol® in Motion, Empowering Menstruators to Find PMS Relief Through Movement

Up to 90% of menstruators experience PMS symptoms 1 , many of which can meaningfully impact day‑to‑day life. Bayer today announced the launch of Midol ® ...

BAYRY : 11.1100 (-1.51%)
BAYZF : 45.0050 (-0.89%)
BAYN : 0.0100 (unch)
Bayer Partners with Luke Bryan to Donate 1 Million Meals Through Feeding America® to Expand Access to Food and Nutrition in Rural Communities

Campaign launches with a Walmart community event and food drive in Clovis, CA on May 14 Additional food collection will take place at Luke Bryan Farm Tour stops in Clovis (May 15) and...

BAYRY : 11.1100 (-1.51%)
BAYZF : 45.0050 (-0.89%)
BAYN : 0.0100 (unch)
Investigational PET Tracer Iodine 124 Evuzamitide from Bayer Met Primary Endpoints in Phase III Study in Patients Suspected to Have Cardiac Amyloidosis

KEY FACTS The Phase III REVEAL study met its primary endpoints demonstrating sensitivity and specificity of iodine 124 evuzamitide (I 124 evuzamitide) positron...

BAYRY : 11.1100 (-1.51%)
BAYZF : 45.0050 (-0.89%)
BAYN : 0.0100 (unch)
Bayer to Acquire Perfuse Therapeutics to Complement Ophthalmology Pipeline

Perfuse Therapeutics’ investigational lead program shows potential to become one of the first disease-modifying treatments for both Glaucoma and Diabetic Retinopathy (DR) High...

BAYRY : 11.1100 (-1.51%)
BAYZF : 45.0050 (-0.89%)
BAYN : 0.0100 (unch)
New Study Highlights Societal Optimism Toward Breakthrough Science, and Rising Anxiety About How Fast the World Is Changing

The Latest Breakthrough Study from Leaps by Bayer and BCG reveals why optimism varies by technology, region, and context, with varying trends in China, Germany, and the US Younger generations...

BAYRY : 11.1100 (-1.51%)
BAYZF : 45.0050 (-0.89%)
BAYN : 0.0100 (unch)

Business Summary

Bayer AG is an international research-based company active in life sciences, polymers, and chemicals. Bayer's operating units include health-care products, material sciences, and crop sciences. Bayer's over-the-counter health-care product division is the third-largest in the world. HealthCare subgroup...

See More

Key Turning Points

3rd Resistance Point 45.1939
2nd Resistance Point 45.0995
1st Resistance Point 45.0522
Last Price 45.0050
1st Support Level 44.9105
2nd Support Level 44.8161
3rd Support Level 44.7688

See More

52-Week High 58.3276
Fibonacci 61.8% 46.4132
Last Price 45.0050
Fibonacci 50% 42.7328
Fibonacci 38.2% 39.0524
52-Week Low 27.1380

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.